Print

Cleveland Biolabs Inc. (CBLI) and Incuron Announce Start of Phase 1 Trial for CBL0137  
10/10/2012 9:26:20 AM

BUFFALO, N.Y., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced that the first patient was dosed in a Phase 1, single agent, dose escalation study of the oral formulation of CBL0137 in subjects with advanced solid tumors that are resistant or refractory to standard of care treatment.
//-->